Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors

NCT06380660 is registered in ClinicalTrials.gov with Acerand Therapeutics (Shanghai) Limited as lead sponsor.

NCT NCT06380660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06380660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
Acerand Therapeutics (Shanghai) Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 22, 2024
Completion date
March 21, 2029
Enrollment
298 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 mutation, brca2 mutation, breast cancer, ovarian cancer, prostate cancer, solid tumor, adult